Aripiprazole augmentation of tranylcypromine in treatment-resistant major depression [8]

Journal of Clinical Psychopharmacology

Volumn 27, Issue 2, 2007, Pages 216-217

  Goforth, Harold W ^a,b   Carroll, Brendan T ^c,d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d Mental Health Service Line   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; LEVOTHYROXINE; LIOTHYRONINE; LITHIUM; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PHENELZINE; SELEGILINE; SERTRALINE; TRANYLCYPROMINE; VENLAFAXINE;

ADD ON THERAPY; ADULT; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TREATMENT FAILURE; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; LETTER; MAJOR DEPRESSION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; PIPERAZINES; QUINOLONES; TRANYLCYPROMINE; TREATMENT OUTCOME;

EID: 34247154031     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000264970.54711.43     Document Type: Letter

References (10)

1. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231-1242.
2. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163: 28-40.
3. Aripiprazole FDA Approved Prescribing Information [Bristol Myers Squibb Web site]. September 22, 2006. Available at: http://www.bms.com/cgi-bin/anybin. pl?sql=select%20PPI%20from%20TB_PRODUCT_PPI%20where%20PPI_SEQ=101&key=PPI. Accessed September 22, 2006.
4. Nemeroff CB. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry. 2005;66(suppl 8):13-21.
5. DeBattista C. Augmentation and combination strategies for depression. J Psychopharmacol. 2006;20(suppl):11-18.
6. Stoll AL, Haura G. Tranylcypromine plus risperidone for treatment refractory major depression. J Clin Psychopharmacol. 2000;20:495-496.
7. Mortimer AM. Novel antipsychotics in schizophrenia. Expert Opin Investig Drugs. 2004;13:315-329.
8. Papakostas GI, Petersen TJ, Kinrys G, et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry. 2005;66:1326-1330.
9. Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry. 2004;16:189-194.
10. Worthington JJ 3rd, Kinrys G, Wygant LE, et al. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol. 2005;20:9-11.